Choledochoduodenal fistula (CDF) is an abnormal passage between the choledochus and duodenum. The most common causes of CDF are cholelithiasis, duodenal ulcer, and tumors. There are mainly two types of fistulas depending on the location. Type 1 is usually present on the longitudinal fold just close to the papilla. Type 2 is present at the duodenal mucosa adjacent to the longitudinal fold and probably caused by larger stones, duodenal ulcer penetration, impacted cystic duct stones, and as a complication of laparoscopic cholecystectomy. In this study, we investigate the characteristics of our patients those were diagnosed with CDF. This is a descriptive study. We retrospectively obtained the data of 21 patients with spontaneous CDF out of 2430 endoscopic retrograde cholangiopancreaticography (ERCP) patients between 2000 and 2014. We analyzed the laboratory results, demographic and etiological features, major clinical presentations, diagnostic methods, and treatment modalities of the patients. The mean age of the 21 patients was 66.6 ± 2.2 years and a female to male ratio was 12:9. In ten patients, interventional procedures were performed via fistulotomy, not through the papilla. The eventual diagnosis was tumor in five patients and stone or sludge in bile ducts in 14 patients. In the remaining two patients, no reason was found as a cause of CDF. Whipple operation was performed in one patient and stents were placed in three patients for malignacy. Among the 14 patients with sludge or stone in bile ducts, ERCP has been therapeutic in ten. One of the remaining patients has been operated for proximal fistula and underwent choledochus exploration and repair of fistula over a T-tube. In the second patient, stone extraction and T-tube drainage were performed. In patients who had bile duct obstruction and got over of jaundice afterwards, one of the most important reasons of this recovery is the development of spontaneous choledochoduodenal fistula. Even if it is very rare, malignancy can be observed in this area. Therefore, it is extremely important to evaluate the papillary area with ERCP and to conduct biopsy; this will make early diagnosis possible in many patients. In these patients, ERCP can both be diagnostic and therapeutic.
Context: Discutăm despre rolul indicatorului de risc de laborator pentru fasceita necrozantă (LRINEC) asupra prognosticului acestei boli. Fasceita necrozantă (NF) se caracterizează prin răspândirea rapidă a infecţiei şi a necrozei ţesutului moale şi a fasciei. Metode: Treizeci de pacienţi (17 bărbaţi, 13 femei, vârsta medie 57,5 ani) au fost trataţi în perioada 2011-2016; au fost analizaţi retrospectiv în ceea ce priveşte vârsta, sexul, agenţii microbiologici izolaţi, modalităţile de tratament şi rata mortalităţii. Rezultate: Majoritatea infecţiilor au fost detectate în perineu (14, 46,7%), alte localizări ale infecţiei fiind regiunea presacrală (3, 10%), regiunea abdominală după intervenţie chirurgicală de elecţie (10,33,3%) şi intervenţie chirurgicală de urgenţă (2, 6.7%). 53,3% dintre pacienţi au prezentat cel puţin un factor comorbid predispozant, cum ar fi diabetul zaharat, hipertensiunea, cardiomiopatia şi insuficienţa cardiacă congestivă. Culturile de ţesut au fost pozitive la 12 (40%) pacienţi. Scorul mediu LRINEC la internare a fost de 8,5 ± 2,85. A existat o corelaţie puternică între scorul LRINEC şi vârsta pacientului (p = 0,018, R = 0,43). Scorul LRINEC nu a fost afectat nici de sex, nici de prezenţa oricăror comorbidităţi. Pacienţii au fost clasificaţi conform sistemului de stadializare Wang şi Wong: 1 pacient în stadiul 1 (3,3%), 15 în stadiul 2 (50%) şi 14 în stadiul 3 (46,7%); pacienţii cu stadii Wang şi Wong mai mari aveau scoruri LRINEC semnificativ mai ridicate. Rata mortalităţii este de 16,7%.
We analyzed the clinical and pathological characteristics of GIST. The most common site of tumor origin was the stomach. The size, mitotic index, and Ki-67 values were to be found high in intermediate- and high-risk groups and metastatic diseases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.